OPN-6602
Multiple Myeloma
Phase 1Active
Key Facts
About Opna Bio
Opna Bio is a private, clinical-stage oncology biotech founded in 2021, leveraging a deep scientific foundation in the Hallmarks of Cancer. The company's strategy centers on designing small molecule inhibitors and degraders with differentiated pharmacokinetic profiles, such as 'pulsatile dosing,' to improve safety and efficacy. Its most advanced assets, the BET inhibitor zavabresib (OPN-2853) and the EP300 inhibitor OPN-6602, are in early-stage clinical trials for myelofibrosis and multiple myeloma, respectively. The leadership team, including co-founder and CSO Gideon Bollag, has a proven track record of advancing multiple drugs to FDA approval.
View full company profileTherapeutic Areas
Other Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| PRG1801 (Anti-BCMA CAR-T) | Pregene Biopharma | Phase 1 |
| CAR-NK Therapy | Pregene Biopharma | Phase 1 |
| Tasquinimod | Active Biotech | Preclinical |
| BCMA CAR-T | Simnova Biotherapeutics | Phase 1 |
| BCMA panCAR (via Orna partnership) | Simnova Biotherapeutics | Preclinical |
| Measovir®-based candidate | Oncovita | Pre-clinical |
| Kyprolis® (carfilzomib) | Cleo Life Sciences | Approved |
| inobrodib (CCS1477) | CellCentric | Phase 1/2 |
| ISB 2001 | Ichnos Glenmark Innovation | Phase 1b |
| In Vivo Cell Therapy | GigaMune | Pre-clinical |
| Hemady | Dexcel Pharma USA | Approved |
| AV-353 | AVEO Oncology | Pre-clinical |